At present, the therapeutic effects of ghrelin on cardiomyopathy are postulated to involve its inhibition of apoptosis of cardiomyocytes, by both GH-IGF-1-dependent [77] and–independent [20, 78, 79] pathways. The gene discussed is IGF1; the disease is cardiomyopathy.